App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome
about
Concise review: new paradigms for Down syndrome research using induced pluripotent stem cells: tackling complex human genetic diseaseDown syndrome: searching for the genetic culpritsOn the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndromeAlpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brainDissecting Alzheimer disease in Down syndrome using mouse modelsThe multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foesA γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APPPrincipal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down SyndromeSynaptic Vesicle Recycling Is Unaffected in the Ts65Dn Mouse Model of Down SyndromeAmyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegenerationSynaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndromeTrisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomesAdaptor proteins intersectin 1 and 2 bind similar proline-rich ligands but are differentially recognized by SH2 domain-containing proteinsCytoskeletal pathologies of Alzheimer diseaseA mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions.Alzheimer disease models and human neuropathology: similarities and differencesMolecular basis of pharmacotherapies for cognition in Down syndromeAlzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition.Excess betaCTF, not Abeta: the culprit in Alzheimer-related endocytic dysfunction.Role of metal ions in the cognitive decline of Down syndrome.A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition.Gene expression levels assessed by CA1 pyramidal neuron and regional hippocampal dissections in Alzheimer's diseaseFunctional transcriptome analysis of the postnatal brain of the Ts1Cje mouse model for Down syndrome reveals global disruption of interferon-related molecular networksPerinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndromeRegional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's diseaseDysregulation of protein trafficking in neurodegeneration.Transcriptional consequence and impaired gametogenesis with high-grade aneuploidy in Arabidopsis thalianaDevelopmentally regulated and evolutionarily conserved expression of SLITRK1 in brain circuits implicated in Tourette syndrome.Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).Autophagy failure in Alzheimer's disease--locating the primary defect.Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up.Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice.Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.Aging, Alzheimer's, and APOE genotype influence the expression and neuronal distribution patterns of microtubule motor protein dynactin-P50Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's diseaseOxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia.Mouse models for Down syndrome-associated developmental cognitive disabilitiesThe use of mouse models for understanding the biology of down syndrome and agingNeuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis
P2860
Q22241147-9FB98D67-61FE-4510-A1D4-82376F445E18Q22241596-783B7C60-8429-4C41-AA0D-5FED0CF2EA15Q22241936-209A051D-C27F-4668-BFC8-E390C8742AF2Q22251262-DC2E51A6-4551-427B-823C-DAA693802E68Q26777254-706DE556-932D-4E0F-A2F8-E78A8FB384AAQ27026919-74B8A49C-B878-464E-AEB0-3AB8D4AFF346Q27314017-308904F2-328A-46F0-8840-9085EE00C2B3Q27322212-94E5FDEA-3866-4846-BEEF-BC596BDF682DQ27324486-C7E78DD8-A340-4232-B5A9-8A8195DFA7B4Q27331605-3C834D82-B13F-4C42-9F30-EEB3C21B5BD0Q28117514-156922AA-6004-4B8C-A9BE-558D9B4E035FQ28118988-00BF6657-7D26-4128-9791-6ABB492DBE7FQ30009586-CB6295A0-6BB5-4E8D-820E-FD23162367EDQ30435267-7B390647-E439-450B-89C4-8EAFF1D76BFFQ30495192-AF8F8EF1-C73C-4FA0-BEE6-CEE38EAF8703Q30499574-91B85EEB-03C6-4579-9BFA-DB75E1D0BC42Q33625613-9327DD46-C91B-43C6-BD2F-E355342E02C6Q33667620-AAB1B936-6EC3-4A51-9E33-3C0B20744711Q33667855-9E005FB4-238A-408D-8A0F-00118FCC6545Q33792132-1118A5A0-B7D2-40EB-BA8B-B39970367C7EQ33808422-A33ABAA5-357A-418C-AAFE-D5A559C2D1FCQ33984420-6E06C12F-1F12-4C46-96C3-99D3A4EA9168Q34012056-CDEC52DA-0FCE-40F6-B61D-2BDE65E21188Q34204889-F1A769A8-33C3-4B41-BF35-DACC1CB7A4B9Q34543633-0E56129C-F49C-4B6D-8799-12548A7AE015Q34545170-AEC0BBE8-5115-4B27-B53C-F0BC3392B209Q34713097-FB60453F-7E48-4EAD-B507-58EAB6929440Q34910081-46627CCA-C949-4537-A165-7BF0ADE67998Q34918986-9D878BA5-8B80-4BAD-9AA1-062DBC09DBC6Q34979826-65844713-6A30-4717-BD48-1A2713C60F32Q34987827-59ACF189-5226-4E5A-9BF1-671318E1AF5AQ35094638-5AA57572-D015-4F7C-AB24-6C26CDAE9C79Q35103335-F49958A2-E016-4A65-B39F-509BC225A066Q35186435-8139A561-8106-4F89-9171-4686B68171BCQ35216177-77D8AA89-DC65-4AFA-BA21-E66C2AF2BEF2Q35359220-B9DDF060-9B14-4310-B32F-D8AC95E28E8BQ35606429-E614909C-F9A5-4C4B-BFA6-9EC950437420Q35661597-EE39CBE0-366D-415F-8743-F750AFA7F7FBQ35810481-DC276299-CCEC-41AE-BECB-3F9FD53F7AC1Q35815212-7B425603-F98E-4BA2-B4F4-E2447967FF80
P2860
App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome
description
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2003
@ast
im Juli 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2003/07/30)
@sk
vědecký článek publikovaný v roce 2003
@cs
wetenschappelijk artikel (gepubliceerd op 2003/07/30)
@nl
наукова стаття, опублікована в липні 2003
@uk
مقالة علمية (نشرت في 30-7-2003)
@ar
name
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@ast
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@en
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@nl
type
label
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@ast
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@en
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@nl
prefLabel
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@ast
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@en
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@nl
P2093
P921
P1476
App gene dosage modulates endo ...... 6 mouse model of down syndrome
@en
P2093
Angela Villar
Anne M Cataldo
Charles J Epstein
Corrinne M Peterhoff
Elaine J Carlson
Nicole B Terio
Ralph A Nixon
Suzana Petanceska
P304
P356
10.1523/JNEUROSCI.23-17-06788.2003
P407
P577
2003-07-01T00:00:00Z